← Back to Search

Other

DZD2269 for Prostate Cancer

Phase 1
Waitlist Available
Research Sponsored by Dizal Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through the study completion, an average of around 1 year
Awards & highlights

Summary

This trial will test a new drug called DZD2269 in patients with advanced prostate cancer that has not responded to other treatments. The study aims to find out if the drug is safe, how it behaves in the body, and if it can help fight the cancer. This is the first time DZD2269 is being tested in humans.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through the study completion, an average of around 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through the study completion, an average of around 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence of AEs and SAEs
Incidence of DLTs
Secondary study objectives
Area under the plasma concentration-time curve (AUC) of DZD2269
Disease Control Rate (DCR);
Drug concentrations of DZD2269 in plasma and urine
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: DZD2269 as monotherapyExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
DZD2269
2021
Completed Phase 1
~80

Find a Location

Who is running the clinical trial?

Dizal PharmaceuticalsLead Sponsor
24 Previous Clinical Trials
2,858 Total Patients Enrolled
~4 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top